High-resolution molecular cytogenetic techniques such as genomic array CGH and MLPA detect submicroscopic chromosome aberrations in patients with unexplained mental retardation. These techniques rapidly change the practice of cytogenetic testing. Additionally, these techniques may improve genotype-phenotype studies of patients with microscopically visible chromosome aberrations, such as Wolf-Hirschhorn syndrome, 18q deletion syndrome and 1p36 deletion syndrome. In order to make the most of high-resolution karyotyping, a similar accuracy of phenotyping is needed to allow researchers and clinicians to make optimal use of the recent advances. International agreements on phenotype nomenclature and the use of computerized 3D face surface models are examples of such improvements in the practice of phenotyping patients with chromosomal anomalies. The combination of high-resolution cytogenetic techniques, a comprehensive, systematic system for phenotyping and optimal data storage will facilitate advances in genotype-phenotype studies and a further deconstruction of chromosomal syndromes. As a result, critical regions or single genes can be determined to be responsible for specific features and malformations.

1.
Allanson JE: Objective techniques for craniofacial assessment: what are the choices? Am J Med Genet 70:1–5 (1997).
2.
Altherr MR, Bengtsson U, et al: Molecular confirmation of Wolf-Hirschhorn syndrome with a subtle translocation of chromosome 4. Am J Hum Genet 49:1235–1242 (1991).
3.
Barrett MT, Scheffer A, et al: Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. Proc Natl Acad Sci USA 101:17765–17770 (2004).
4.
Bi W, Saifi GM, et al: Mutations of RAI1, a PHD-containing protein, in nondeletion patients with Smith-Magenis syndrome. Hum Genet 115:515–524 (2004).
5.
Biesecker LG: Mapping phenotypes to language: a proposal to organize and standardize the clinical descriptions of malformations. Clin Genet 68:320–326 (2005).
6.
Bonaglia MC, Giorda R, et al: Disruption of the ProSAP2 gene in a t(12;22)(q24.1;q13.3) is associated with the 22q13.3 deletion syndrome. Am J Hum Genet 69:261–268 (2001).
7.
Bonaglia MC, Giorda R, et al: Identification of a recurrent breakpoint within the SHANK3 gene in the 22q13.3 deletion syndrome. J Med Genet 43:822–828 (2006).
8.
Brewer C, Holloway S, et al: A chromosomal deletion map of human malformations. Am J Hum Genet 63:1153–1159 (1998).
9.
Brewer C, Holloway S, et al: A chromosomal duplication map of malformations: regions of suspected haplo- and triplolethality – and tolerance of segmental aneuploidy–in humans. Am J Hum Genet 64:1702–1708 (1999).
10.
Brown S, Russo J, et al: The 13q- syndrome: the molecular definition of a critical deletion region in band 13q32. Am J Hum Genet 57:859–866 (1995).
11.
Brown SA, Warburton D, et al: Holoprosencephaly due to mutations in ZIC2, a homologue of Drosophila odd-paired. Nat Genet 20:180–183 (1998).
12.
Church DM, Bengtsson U, et al: Molecular definition of deletions of different segments of distal 5p that result in distinct phenotypic features. Am J Hum Genet 56:1162–1172 (1995).
13.
Cody JD, Ghidoni PD, et al: Congenital anomalies and anthropometry of 42 individuals with deletions of chromosome 18q. Am J Med Genet 85:455–462 (1999).
14.
De Grouchy J, Royer P, et al: Partial deletion of the long arms of the chromosome 18. Pathol Biol (Paris) 12:579–582 (1964).
15.
de Vries BB, Pfundt R, et al: Diagnostic genome profiling in mental retardation. Am J Hum Genet 77:606–616 (2005).
16.
DiLiberti JH, Olson DP: Photogrammetric evaluation in clinical genetics: theoretical considerations and experimental results. Am J Med Genet 39:161–166 (1991).
17.
Estabrooks LL, Rao KW, et al: Preliminary phenotypic map of chromosome 4p16 based on 4p deletions. Am J Med Genet 57:581–586 (1995).
18.
Feenstra I, Fang J, et al: European Cytogeneticists Association Register of Unbalanced Chromosome Aberrations (ECARUCA); An online database for rare chromosome abnormalities. Eur J Med Genet 49:279–291 (2006).
19.
Freimer N, Sabatti C: The human phenome project. Nat Genet 34:15–21 (2003).
20.
Garn SM, Smith BH, et al: Applications of pattern profile analysis to malformations of the head and face. Radiology 150:683–690 (1984).
21.
Garn SM, Lavelle M, et al: Quantification of dysmorphogenesis: pattern variability index, sigma z. AJR Am J Roentgenol 144:365–369 (1985).
22.
Gersh M, Goodart SA, et al: Evidence for a distinct region causing a cat-like cry in patients with 5p deletions. Am J Hum Genet 56:1404–1410 (1995).
23.
Girirajan S, Elsas LJ 2nd, et al: RAI1 variations in Smith-Magenis syndrome patients without 17p11.2 deletions. J Med Genet 42:820–828 (2005).
24.
Greenberg F, Guzzetta V, et al: Molecular analysis of the Smith-Magenis syndrome: a possible contiguous-gene syndrome associated with del(17)(p11.2). Am J Hum Genet 49:1207–1218 (1991).
25.
Hall JG: A clinician’s plea. Nat Genet 33:440–442 (2003).
26.
Hammond P, Hutton TJ, et al: Discriminating power of localized three-dimensional facial morphology. Am J Hum Genet 77:999–1010 (2005).
27.
Heilstedt HA, Ballif BC, et al: Physical map of 1p36, placement of breakpoints in monosomy 1p36, and clinical characterization of the syndrome. Am J Hum Genet 72:1200–1212 (2003).
28.
Hirschhorn K, Cooper HL, et al: Deletion of short arms of chromosome 4–5 in a child with defects of midline fusion. Humangenetik 1:479–482 (1965).
29.
Jerome LA, Papaioannou VE: DiGeorge syndrome phenotype in mice mutant for the T-box gene, Tbx1. Nat Genet 27:286–291 (2001).
30.
Johnson VP, Altherr MR, et al: FISH detection of Wolf-Hirschhorn syndrome: exclusion of D4F26 as critical site. Am J Med Genet 52:70–74 (1994).
31.
Kleefstra T, Smidt M, et al: Disruption of the gene Euchromatin Histone Methyl Transferase1 (Eu-HMTase1) is associated with the 9q34 subtelomeric deletion syndrome. J Med Genet 42:299–306 (2005).
32.
Kleefstra T, Brunner HG, et al: Loss of function mutations in euchromatin histone methyl transferase 1 (EHMT1) cause the 9q34 subtelomeric deletion syndrome. Am J Hum Genet 79:370–377 (2006).
33.
Kline AD, White ME, et al: Molecular analysis of the 18q- syndrome – and correlation with phenotype. Am J Hum Genet 52:895–906 (1993).
34.
Koolen DA, Nillesen WM, et al: Screening for subtelomeric rearrangements in 210 patients with unexplained mental retardation using multiplex ligation dependent probe amplification (MLPA). J Med Genet 41:892–899 (2004).
35.
Koolen DA, Reardon W, et al: Molecular characterisation of patients with subtelomeric 22q abnormalities using chromosome specific array-based comparative genomic hybridisation. Eur J Hum Genet 13:1019–1024 (2005).
36.
Koolen DA, Herbergs J, et al: Holoprosencephaly and preaxial polydactyly associated with a 1.24 Mb duplication encompassing FBXW11 at 5q35.1. J Hum Genet 51:721–726 (2006).
37.
Kreuz FR, Wittwer BH: Del(2q)–cause of the wrinkly skin syndrome? Clin Genet 43:132–138 (1993).
38.
Kurotaki N, Imaizumi K, et al: Haploinsufficiency of NSD1 causes Sotos syndrome. Nat Genet 30:365–366 (2002).
39.
Lejeune J, Lafourcade J, et al: 3 Cases of partial deletion of the short arm of chromosome 5. C R Hebd Seances Acad Sci 257:3098–3102 (1963).
40.
Loos HS, Wieczorek D, et al: Computer-based recognition of dysmorphic faces. Eur J Hum Genet 11:555–560 (2003).
41.
Mainardi PC, Perfumo C, et al: Clinical and molecular characterisation of 80 patients with 5p deletion: genotype-phenotype correlation. J Med Genet 38:151–158 (2001).
42.
Merks JH, van Karnebeek CD, et al: Phenotypic abnormalities: terminology and classification. Am J Med Genet A 123:211–230 (2003).
43.
Miller DA, Warburton D, et al: Clustering in deleted short-arm length among 25 cases with a Bp-chromosome. Cytogenetics 8:109–116 (1969).
44.
Miyazaki K, Yamanaka T, et al: Interstitial deletion 2q32.1→q34 in a child with half normal activity of ribulose 5-phosphate 3-epimerase (RPE). J Med Genet 25:850–851 (1988).
45.
Muenke M, Gurrieri F, et al: Linkage of a human brain malformation, familial holoprosencephaly, to chromosome 7 and evidence for genetic heterogeneity. Proc Natl Acad Sci USA 91:8102–8106 (1994).
46.
Niebuhr E: The Cri du Chat syndrome: epidemiology, cytogenetics, and clinical features. Hum Genet 44:227–275 (1978a).
47.
Niebuhr E: Cytologic observations in 35 individuals with a 5p– karyotype. Hum Genet 42:143–156 (1978b).
48.
Overhauser J, Huang X, et al: Molecular and phenotypic mapping of the short arm of chromosome 5: sublocalization of the critical region for the cri-du-chat syndrome. Hum Mol Genet 3:247–252 (1994).
49.
Overhauser J, Mitchell HF, et al: Physical mapping of the holoprosencephaly critical region in 18p11.3. Am J Hum Genet 57:1080–1085 (1995).
50.
Palmer CG, Heerema N, et al: Deletions in chromosome 2 and fragile sites. Am J Med Genet 36:214–218 (1990).
51.
Petrij F, Giles RH, et al: Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 376:348–351 (1995).
52.
Pinkel D, Segraves R, et al: High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 20:207–211 (1998).
53.
Prasad C, Prasad AN, et al: Genetic evaluation of pervasive developmental disorders: the terminal 22q13 deletion syndrome may represent a recognizable phenotype. Clin Genet 57:103–109 (2000).
54.
Rauch A, Beese M, et al: A novel 5q35.3 subtelomeric deletion syndrome. Am J Med Genet A 121:1–8 (2003).
55.
Rauch A, Zink S, et al: Systematic assessment of atypical deletions reveals genotype-phenotype correlation in 22q11.2. J Med Genet 42:871–876 (2005).
56.
Redon R, Rio M, et al: Tiling path resolution mapping of constitutional 1p36 deletions by array-CGH: contiguous gene deletion or ‘deletion with positional effect’ syndrome? J Med Genet 42:166–171 (2005).
57.
Richtsmeier JT: Comparative study of normal, Crouzon, and Apert craniofacial morphology using finite element scaling analysis. Am J Phys Anthropol 74:473–493 (1987).
58.
Rodriguez L, Zollino M, et al: The new Wolf-Hirschhorn syndrome critical region (WHSCR-2): a description of a second case. Am J Med Genet A 136:175–178 (2005).
59.
Roelfsema JH, White SJ, et al: Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease. Am J Hum Genet 76:572–580 (2005).
60.
Schell U, Wienberg J, et al: Molecular characterization of breakpoints in patients with holoprosencephaly and definition of the HPE2 critical region 2p21. Hum Mol Genet 5:223–229 (1996).
61.
Schinzel A: Zurich Cytogenetics Database (1994).
62.
Schinzel A: Catalogue of Unbalanced Chromosome Aberrations in Man. (De Gruyter, Berlin 2001).
63.
Schouten JP, McElgunn CJ, et al: Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30:e57 (2002).
64.
Shaffer LG, Lupski JR: Molecular mechanisms for constitutional chromosomal rearrangements in humans. Annu Rev Genet 34:297–329 (2000).
65.
Shaner DJ, Peterson AE, et al: Soft tissue facial resemblance in families and syndrome-affected individuals. Am J Med Genet 102:330–341 (2001).
66.
Shapira SK, McCaskill C, et al: Chromosome 1p36 deletions: the clinical phenotype and molecular characterization of a common newly delineated syndrome. Am J Hum Genet 61:642–650 (1997).
67.
Slager RE, Newton TL, et al: Mutations in RAI1 associated with Smith-Magenis syndrome. Nat Genet 33:466–468 (2003).
68.
Slater HR, Bailey DK, et al: High-resolution identification of chromosomal abnormalities using oligonucleotide arrays containing 116,204 SNPs. Am J Hum Genet 77:709–726 (2005).
69.
Smith AC, Dykens E, et al: Behavioral phenotype of Smith-Magenis syndrome (del 17p11.2). Am J Med Genet 81:179–185 (1998).
70.
Speicher MR, Carter NP: The new cytogenetics: blurring the boundaries with molecular biology. Nat Rev Genet 6:782–792 (2005).
71.
Stec I, Wright TJ, et al: WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma. Hum Mol Genet 7:1071–1082 (1998).
72.
Stewart DR, Huang A, et al: Subtelomeric deletions of chromosome 9q: a novel microdeletion syndrome. Am J Med Genet A 128:340–351 (2004).
73.
Tassabehji M, Hammond P, et al: GTF2IRD1 in craniofacial development of humans and mice. Science 310:1184–1187 (2005).
74.
Van Buggenhout G, Melotte C, et al: Mild Wolf-Hirschhorn syndrome: micro-array CGH analysis of atypical 4p16.3 deletions enables refinement of the genotype-phenotype map. J Med Genet 41:691–698 (2004).
75.
Van Buggenhout G, Van Ravenswaaij-Arts C, et al: The del(2)(q32.2q33) deletion syndrome defined by clinical and molecular characterization of four patients. Eur J Med Genet 48:276–289 (2005).
76.
Veltman JA, Jonkers Y, et al: Definition of a critical region on chromosome 18 for congenital aural atresia by array CGH. Am J Hum Genet 72:1578–1584 (2003).
77.
Vissers LE, Veltman JA, et al: Identification of disease genes by whole genome CGH arrays. Hum Mol Genet 14 Spec No. 2:R215–223 (2005).
78.
Vlangos CN, Yim DK, et al: Refinement of the Smith-Magenis syndrome critical region to approximately 950 kb and assessment of 17p11.2 deletions. Are all deletions created equally? Mol Genet Metab 79:134–141 (2003).
79.
Vogels A, Haegeman J, et al: Pierre-Robin sequence and severe mental retardation with chaotic behaviour associated with a small interstitial deletion in the long arm of chromosome 2 (del(2)(q331q333)). Genet Couns 8:249–252 (1997).
80.
Wallis DE, Roessler E, et al: Mutations in the homeodomain of the human SIX3 gene cause holoprosencephaly. Nat Genet 22:196–198 (1999).
81.
Wilson HL, Wong AC, et al: Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms. J Med Genet 40:575–584 (2003).
82.
Wilson MG, Towner JW, et al: Genetic and clinical studies in 13 patients with the Wolf-Hirschhorn syndrome [del(4p)]. Hum Genet 59:297–307 (1981).
83.
Winter RM: What’s in a face? Nat Genet 12:124–129 (1996).
84.
Wolf U, Reinwein H, et al: Deficiency on the short arms of a chromosome No. 4. Humangenetik 1:397–413 (1965).
85.
Wright TJ, Ricke DO, et al: A transcript map of the newly defined 165 kb Wolf-Hirschhorn syndrome critical region. Hum Mol Genet 6:317–324 (1997).
86.
Wright TJ, Costa JL, et al: Comparative analysis of a novel gene from the Wolf-Hirschhorn/Pitt-Rogers-Danks syndrome critical region. Genomics 59:203–212 (1999).
87.
Wu YQ, Heilstedt HA, et al: Molecular refinement of the 1p36 deletion syndrome reveals size diversity and a preponderance of maternally derived deletions. Hum Mol Genet 8:313–321 (1999).
88.
Yagi H, Furutani Y, et al: Role of TBX1 in human del22q11.2 syndrome. Lancet 362:1366–1373 (2003).
89.
Yu W, Ballif BC, et al: Development of a comparative genomic hybridization microarray and demonstration of its utility with 25 well-characterized 1p36 deletions. Hum Mol Genet 12:2145–2152 (2003).
90.
Zhang X, Snijders A, et al: High-resolution mapping of genotype-phenotype relationships in Cri du Chat syndrome using array comparative genomic hybridization. Am J Hum Genet 76:312–326 (2005).
91.
Zollino M, Di Stefano C, et al: Genotype-phenotype correlations and clinical diagnostic criteria in Wolf-Hirschhorn syndrome. Am J Med Genet 94:254–261 (2000).
92.
Zollino M, Lecce R, et al: Mapping the Wolf-Hirschhorn syndrome phenotype outside the currently accepted WHS critical region and defining a new critical region, WHSCR-2. Am J Hum Genet 72:590–597 (2003).
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.